Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 2/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 10/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3758866 | 0.84 | CYP19A1 (0.52) | SHBGCYP19A1ALDH1A1MEN1KMT2A | |
| SCHEMBL3746805 | 0.84 | CYP19A1 (0.52) | SHBGCYP19A1ALDH1A1MEN1KMT2A | |
| SCHEMBL3748482 | 0.76 | SHBG (0.57) | SHBGCYP19A1ALDH1A1MEN1KMT2A | |
| SCHEMBL3751402 | 0.75 | SHBG (0.54) | SHBGCYP19A1ALDH1A1MEN1KMT2A | |
| SCHEMBL3748862 | 0.75 | SHBG (0.54) | SHBGCYP19A1ALDH1A1MEN1KMT2A | |
| SCHEMBL3750362 | 0.74 | CYP19A1 (0.48) | SHBGCYP19A1ALDH1A1MEN1KMT2A | |
| SCHEMBL8340653 | 0.70 | SHBG (0.82) | SHBGCYP19A1ALDH1A1MEN1KMT2A | |
| SCHEMBL8340651 | 0.70 | SHBG (0.82) | SHBGCYP19A1ALDH1A1MEN1KMT2A | |
| Calusterone SCHEMBL4509 | 0.70 | SHBG (1.00) | SHBGCYP19A1ALDH1A1CYP3A4AR | |
| Bolasterone SCHEMBL145066 | 0.70 | SHBG (1.00) | SHBGCYP19A1ALDH1A1CYP3A4AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292184-A1 | 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | BAYER SCHERING PHARMA AG (DE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292184-A1 | 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | HSD17B11, HSD17B7, NR5A1 | SHBG 24/4885CYP19A1 14/4885ALDH1A1 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.